How it works
SNAP-8 is an N-terminally acetylated octapeptide derived from the N-terminal sequence of SNAP-25, a component of the SNARE complex that mediates vesicle fusion. The design premise is competitive: the peptide mimics the SNAP-25 fragment and is studied for whether it can occupy that position in complex assembly, reducing fusion efficiency. It is an extension of the shorter hexapeptide argireline, with two additional residues intended to improve affinity. The dermal research context is expression-line formation, studied topically rather than systemically.
Learn more about the science →Certificate of Analysis+
LC-MS identity, HPLC purity, mass spec confirmation, endotoxin by LAL, appearance. Third-party ISO-17025 verified.
View full certificate →Specifications+
Storage & handling+
Lyophilized: −20°C, protected from light. Reconstituted: 2–8°C. The methionine residue is oxidation-sensitive — minimise headspace and air exposure.
We ship in insulated parcels with phase-change cooling and a tamper-evident seal.
FAQs+
How does SNAP-8 differ from argireline?+
Two residues longer. Both mimic the N-terminal end of SNAP-25; SNAP-8 extends the hexapeptide with the intent of improving affinity for the SNARE complex.
Why is SNAP-8 in Derma?+
Derma collects compounds studied in skin and connective-tissue contexts. SNAP-8's published research is dermal and topical rather than systemic.
Does it act on the same target as botulinum toxin?+
The same complex, by a different route. Botulinum toxin cleaves SNAP-25 enzymatically; SNAP-8 is studied as a competitive mimic of a SNAP-25 fragment. The mechanisms are not equivalent and the effect sizes in the literature are not comparable.
Any handling specifics?+
The methionine residue oxidises. Keep air exposure low on reconstitution, and treat an unexpected +16 Da in mass spec as oxidation rather than a sequence error.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Blanes-Mira C. et al. Int J Cosmet Sci 24 (2002): 303–310.
- [02] Ruiz M.A. et al. J Cosmet Dermatol 8 (2009): 214–221.
Verified buyer notes
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”